Literature DB >> 19746196

Robust Non-inferiority Tests for Potency of a Test Drug Against a Reference Drug: (To appear in Statistics in Biopharmaceutical Research ).

Michael P Fay1, Farzad Noubary, Allan Saul.   

Abstract

In comparing test formulations of a drug product to reference formulations it is necessary to check that the test formulation has as much biologic activity as the reference within some indifference zone. A modern method for testing this relative potency is to fit a nonlinear model of the dose response curve, constrained such that the dose-response of the test is modeled with the same function as the reference except for a multiplicative parameter on the dose. This method works well as long as the nonlinear model fits the data. Although tests of this fit are mentioned in the literature, how relative potency should be measured when those tests fail has not been addressed. We study the use of the sandwich estimator of variance for this non-inferiority potency problem when the model does not fit the data. We focus on the simple linear model. Using the sandwich variance, the inferences are asymptotically valid even if the model does not hold. We discuss interpretation of the results under the misspecified linear model, and show by simulation that the method performs well in some practical cases. Finally, we give advice for designing a study that uses these methods.

Entities:  

Year:  2009        PMID: 19746196      PMCID: PMC2739393          DOI: 10.1198/sbr.2009.0023.

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  7 in total

1.  Small-sample adjustments for Wald-type tests using sandwich estimators.

Authors:  M P Fay; B I Graubard
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

Review 2.  Statistical considerations for vaccine immunogenicity trials. Part 1: Introduction and bioassay design and analysis.

Authors:  Brian D Plikaytis; George M Carlone
Journal:  Vaccine       Date:  2005-02-18       Impact factor: 3.641

3.  Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data.

Authors:  Paul G Gottschalk; John R Dunn
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

4.  Guidelines for immunoassay data processing.

Authors:  R A Dudley; P Edwards; R P Ekins; D J Finney; I G McKenzie; G M Raab; D Rodbard; R P Rodgers
Journal:  Clin Chem       Date:  1985-08       Impact factor: 8.327

5.  Determination of parallelism and nonparallelism in bioassay dilution curves.

Authors:  B D Plikaytis; P F Holder; L B Pais; S E Maslanka; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

6.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

7.  Potency assay design for adjuvanted recombinant proteins as malaria vaccines.

Authors:  Birgitte K Giersing; Filip Dubovsky; Allan Saul; Francoise Denamur; Philip Minor; Bruce Meade
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.